Literature DB >> 8363379

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.

J M Woods1, R C Bethell, J A Coates, N Healy, S A Hiscox, B A Pearson, D M Ryan, J Ticehurst, J Tilling, S M Walcott.   

Abstract

The sialidase (neuraminidase) inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) has been examined for the ability to inhibit the growth of a wide range of influenza A and B viruses in vitro in comparison with amantadine, rimantadine, and ribavirin. 4-Guanidino-Neu5Ac2en inhibited plaque formation by laboratory-passaged strains of influenza A and B viruses, with 50% inhibitory concentrations ranging from 0.005 to 0.014 microM. A wider range of values (0.02 to 16 microM) was obtained with more recent clinical isolates, but in all cases 4-guanidino-Neu5Ac2en inhibited influenza A and B virus replication at lower concentrations than amantadine, rimantadine, or ribavirin. Inhibition by 4-guanidino-Neu5Ac2en was not obviously affected by the passage history of the viruses or by resistance to amantadine or rimantadine. 4-Guanidino-Neu5Ac2en was a very potent inhibitor of the sialidases of all the influenza viruses examined, with 50% inhibitory concentrations ranging from 0.00064 to 0.0079 microM. No cytotoxicity was observed with 4-guanidino-Neu5Ac2en at up to 10 mM. 4-Guanidino-Neu5Ac2en therefore represents a new potent and selective inhibitor of influenza A and B virus sialidase activity and replication in vitro.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363379      PMCID: PMC187997          DOI: 10.1128/AAC.37.7.1473

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance.

Authors:  R B Belshe; B Burk; F Newman; R L Cerruti; I S Sim
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

2.  Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus.

Authors:  J S Robertson; J S Bootman; R Newman; J S Oxford; R S Daniels; R G Webster; G C Schild
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

3.  Growth control of human foreskin fibroblasts and inhibition of extracellular sialidase activity by 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.

Authors:  S Usuki; P Hoops; C C Sweeley
Journal:  J Biol Chem       Date:  1988-08-05       Impact factor: 5.157

4.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors:  R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

5.  Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates.

Authors:  R M Pemberton; R Jennings; C W Potter; J S Oxford
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

6.  Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs.

Authors:  J S Robertson; C W Naeve; R G Webster; J S Bootman; R Newman; G C Schild
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

7.  Children with influenza A infection: treatment with rimantadine.

Authors:  C B Hall; R Dolin; C L Gala; D M Markovitz; Y Q Zhang; P H Madore; F A Disney; W B Talpey; J L Green; A B Francis
Journal:  Pediatrics       Date:  1987-08       Impact factor: 7.124

8.  The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity.

Authors:  L G Baum; J C Paulson
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

9.  In vitro cytotoxicity studies with the fish hepatoma cell line, PLHC-1 (Poeciliopsis lucida).

Authors:  H Babich; D W Rosenberg; E Borenfreund
Journal:  Ecotoxicol Environ Saf       Date:  1991-06       Impact factor: 6.291

10.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.

Authors:  F G Hayden; R B Belshe; R D Clover; A J Hay; M G Oakes; W Soo
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

View more
  73 in total

1.  Zanamivir for influenza: a public health perspective. Its use will require careful management by GPs.

Authors:  J S Nguyen-Van-Tam
Journal:  BMJ       Date:  1999-09-11

2.  Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation.

Authors:  A W Peng; S Milleri; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 3.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

4.  Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity.

Authors:  L R Hoffman; I D Kuntz; J M White
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 5.  Influenza.

Authors:  Tom Jefferson
Journal:  BMJ Clin Evid       Date:  2009-03-12

6.  CD15 expression in human myeloid cell differentiation is regulated by sialidase activity.

Authors:  Samah Zeineb Gadhoum; Robert Sackstein
Journal:  Nat Chem Biol       Date:  2008-10-19       Impact factor: 15.040

Review 7.  Zanamivir.

Authors:  S L Waghorn; K L Goa
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

8.  Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.

Authors:  S Bantia; A A Ghate; S L Ananth; Y S Babu; G M Air; G M Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

9.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

10.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-01-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.